Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
RNS that? Seems very odd and Synairgen are are not in the habit of RNS;s for the sake of it.
Oak agreed.....people need to stop reading just what is there and think of what else is not written there....think there is a lot more to that RNS that meets the eye.
Sharedealer, care to share your thoughts?
I don't know anything about this ESWI bar what I've seen on the website this morning - but just going by the sponsors alone, it would seem quite a good venue to be demonstrating your home run respiratory disease drug.
Oakleaf72.
You are right; they isually issued an RNS on a significant piece of information. However, the company now has more sophistication to its marketing techniques than was the case previously. I have been impressed by Richard Marsden's recent confident presentations together with the quality of his slides.
Is it possible that they are drawing attention to the formative case for investment to date, by pulling together all the currently available information in one place? Added up, it presents a powerful basis for investment. The fact that Dr. Monk is presenting and that it is a poster display contribute to my thinking. The big news thus far has come by the direct RNS channel, followed by Richard Marsden giving further clarification by a Proactive Investors interview, and elsewhere.
That having been said, I hope that you are right, and that there is someting else to add to take the company a step forward?
Regards and good wishes.
Thanks TL,
I get that and your sentiment is shared by many on another board but I am still asking myself what the objective is. Having been here for over a year now I guess I'm stuck in SNG's old ways but I still don't see the point of RNS's like that, whoever you are.
Best
I have seen these presentation RNS's on a number of other Pharma shares, nothing new is ever released.
To date they have all been a non-event. I don't understand why they bother.
So what is the “contains inside information” that no one (outside of SNG) currently knows, all about?
After tonight If there is none RM will look silly.
If there is some - the market will look silly!
Doc83 - I believe that statement is other Synairgen RNS's as well and refers to the RNS itself (Ie completion of P3 recruitment had the same statement) - it doesn't refer to upcoming new information.
For context. see this RNS from 4D Pharma in September. They often RNS this type of event. The presentations/posters did not contain anything new. Just interpretation of known data. It's about marketing. Marketing can be material from a regulatory perspective or at least a company can take advantage of the RNS service in these circumstances.
https://www.lse.co.uk/rns/DDDD/4d-pharma-presents-two-posters-at-esmo-congress-eg9s8rv825jnwpv.html
The materiality is that SNG are presenting at this important event. That's positive. If they didn't tell us then we might be grumpy about it and SNG would miss an opportunity to make it more widely known to investors.
I wouldn't rule out something positive in terms of what is said/how the message is related etc. but they are meant to include that in the RNS if there is.
It's just very good to see SNG out there.
For full disclosure I am not invested in 4D - I have been previously - hence my knowing about them and I thought it useful to share that this is not an unusual RNS from SNG today.
Abstract: 269 is mentioned in the RNS.
On the conference website the 'End of abstract submission' is given as 30th sept 2021.
Submission of an abstract acknowledges your acceptance for the abstract to be published in the official Congress publications. The presenting author is required to ensure that all co-authors are aware of the content of the abstract and agree to its submission, before submitting the abstract.
So, IMO this RNS (and conference) has been in the offing for some time. The BOD didn't just decide to present at this conference yesterday, it will have been diarised some months ago give the submission date (30th Sept). So I wouldn't worry about it - all good and expected progress getting the SNG001 story out there to industry professionals and beyond.
You mean in the conference Ndn17?
Sorry to ask again, but how do we watch this tonight? On the ESWI site it wants me to pay €495! I’m guessing I’m looking in the wrong place…
Thank you Ndn17, found it. I note there was a predominantly Univ. of Southampton session on 4th too. Great things coming out of Univ. Southampton on respiratory front, they deserve it.
In my mind, they signed up for the conference (and submitted their variants data) before 30th Sept, so Monk's address will have been written pre-Omni and pre-Sprinter end. It will be interesting to know what will be said.
Can we watch it? I dont see the option to register to watch
Doc83 - "So what is the 'contains inside information' that no one (outside of SNG) currently knows, all about?"
Maybe the news is that their in-development covid drug is being presented at a flu conference? Covid isn't flu. So if they' re beginning to push this strongly as a broad-spectrum antiviral, that's price-sensitive information.
I realize it's news that we'd already inferred. But this is further confirmation of it, and it did affect this morning's price.
I see nothing new here but I did find the references to asthma and COPD out of place given the recent trials! Not ‘out of place’ given what drug is for but more what we have recently been through. Seemed like a little ‘but also does this’ and less ‘actually really good at this’
I also agree the RNS is weird compared to the old nature a dependability of RNS’
I also agree that we would be peeved if we were not told!
Basically I want 8pm to arrive and be smiling because there was news…. And it was unbelievably good
Doc83, that's what it costs to watch the presentation - its not free!!
Well as much as I’d like to watch the presentation, I’m not paying €495. Shame.
If anyone has stumped up, or has found a way to watch it for free, please keep us updated!
Have you got access NDN? Did you pay, or would you mind letting me know how I can view it?
Fair enough! Keep me posted if you do indeed have access ;)
NDN is in sng hq for the 'Virtual' conference smh.
Even the conference call is double blinded!! lol